微波治疗初期酒渣鼻

目的：观察微波对初期酒渣鼻的治疗作用。方法：用微波治疗28例初期酒渣鼻,观察治疗前后皮 损变化。结果：治愈18例,总有效率100％,未见严重不良反应。结论：微波疗法是治疗初期酒渣鼻的安全有效方法。     

运脾颗粒对慢传输型便秘患者结肠动力的影响

为探讨运脾颗粒对慢传输型便秘患者结肠动力的影响,观察其临床疗效,选择116例慢传输型便秘患者,随机分为治疗组和对照组,各58例。治疗组予运脾颗粒治疗,对照组予肠动力药枸橼酸莫沙必利片剂治疗。两组均以30d为一疗程。观察两组治疗前后48h、72h结肠传输试验结果及治疗前后症状积分,统计药物不良反应。结果显示,治疗组总有效率（91．4％）明显高于对照组（75．9％）,P〈0．05;治疗组治疗后结肠传输功能和症状改善均优于对照组,P〈0．05;治疗组治疗过程中无不良反应,对照组仅见轻度胃肠道反应,均未影响治疗。结果表明,运脾颗粒能有效改善胃肠动力,是治疗慢传输型便秘的安全有效药物。     

清热除湿汤加减联合IPL治疗轻中度脾胃湿热型玫瑰痤疮疗效研究

目的：探讨清热除湿汤加减联合强脉冲光（Intense pulsed light,IPL）治疗轻中度脾胃湿热型玫瑰痤疮的疗效。方法：选取2018年2月-2021年2月在笔者医院确诊的100例轻中度脾胃湿热型玫瑰痤疮患者，采用简单随机分组将患者分为观察组和对照组，每组50例。对照组采用IPL治疗，观察组采用清热除湿汤加减联合IPL治疗，均持续治疗4个月。评价患者疗效和治疗前后中医证候积分。分别于治疗前后采用玫瑰痤疮医师全球评分（Physician’sglobalassessment,PGA）对患者玫瑰痤疮情况进行评分；分别于治疗前、治疗后2个月和治疗后4个月，使用皮肤病生活质量指数量表（Dermatologylife qualityindex,DLQI）评估患者生活质量。记录两组治疗期间的不良反应发生情况。结果：观察组治疗有效率为92.00%，明显高于对照组的76.00%，差异有统计学意义（P<0.05）；治疗后，观察组中医证候积分明显低于对照组，观察组患者玫瑰痤疮改善程度明显优于对照组，生活质量明显高于对照组，差异均有统计学意义（P<0.05）。观察组患者治疗期间的不良反应发...     

强脉冲光联合果酸对轻中度痤疮的疗效及安全

目的 分析对轻中度痤疮患者给予强脉冲光联合果酸治疗的效果及安全性。方法 选择杭州艺星医 疗美容医院2023年1月-10月收治的100例轻中度痤疮患者为研究对象,采用随机数字表法分为对照组和试 验组,各50例。对照组采用强脉冲光治疗,试验组在对照组基础上采用强脉冲光联合果酸治疗,比较两组 临床疗效、生活质量、痤疮严重程度及不良反应发生情况。结果 试验组治疗总有效率为98.00%,高于对 照组的88.00%（P ＜0.05）;试验组治疗后DLQI评分低于对照组（P ＜0.05）;试验组治疗后ACSI评分低于 对照组（P＜0.05）;两组不良反应发生率比较,差异无统计学意义（P＞0.05）。结论 强脉冲光联合果酸 治疗轻中度痤疮的效果良好,可有效减轻患者的痤疮症状,有利于改善其生活质量,且不会增加不良反应 发生风险,应用安全性较高。     

超脉冲二氧化碳点阵激光治疗稳定期白癜风的临床效果

目的 探究超脉冲二氧化碳点阵激光治疗稳定期白癜风的临床效果。方法 以我院2019年1月-2020年10月收治的80例稳定期白癜风患者为研究对象,通过简单随机化法分为对照组（n=40）和试验组（n=40）,对照组采用常规药物治疗,试验组则在对照组基础实施超脉冲二氧化碳点阵激光治疗,比较两组治疗效果、生活质量评分、炎性因子水平及不良反应发生情况。结果 试验组的总有效率为90.00%,高于对照组的70.00%（P＜0.05）;两组治疗后生活质量评分均高于治疗前,且试验组生活质量评分高于对照组（P＜0.05）;两组炎性因子水平均低于治疗前,且试验组低于对照组（P＜0.05）;两组不良反应发生率比较,差异无统计学意义（P＞0.05）。结论 与常规药物治疗相比,超脉冲二氧化碳点阵激光治疗效果更佳,可有效改善患者生活质量,降低炎性因子水平,且不会增加不良反应,是一种安全、有效的治疗方案。     

2790 nm钇-钪-镓-石榴石点阵激光治疗凹陷性痤疮瘢痕的疗效

目的 观察评估2790 nm钇-钪-镓石榴石(YSGG)点阵激光治疗面部凹陷性痤疮瘢痕的疗效及安全性.方法 将患者随机分成两组,A组使用2790 nm YSGG点阵激光非剥脱模式治疗1次,再以剥脱模式治疗;B组仅使用2790 nm YSGG点阵激光非剥脱模式进行治疗.每组共治疗4次,每间隔6周治疗1次,治疗前后均以VISIA(R)数字皮肤分析系统对面部瘢痕和肤质进行评分和统计比较,并由患者、医师共同评价满意度.结果 38例患者均完成4次治疗,治疗后所有凹陷性瘢痕均有不同程度的改善,A、B组治愈率分别为56.0％和30.8％,总有效率81.6％,无1例严重不良反应,A组优于B组.结论 2790 nm YSGG点阵激光具有效果明显、精确度高、损伤小、操作方便的优点,且治疗后并发症少、色素沉着程度轻,2790 nm YSGG点阵激光是治疗面部浅表瘢痕安全、有效的方法之一.     

鼻部倒模加He－Ne激光治疗非螨性酒渣鼻疗效观察

本文对３２８例经曲氏检螨法检螨，其感染度在正常范围内（４０条／人以内），可以排除蠕形螨感染因素，皮损仅限于鼻部的酒渣鼻患者，随机分成三组．Ａ组２２８例，采用鼻部倒模加Ｈｅ－Ｎｅ激光照射治疗．隔日１次，８次为１疗程．Ｂ组５０例，单纯外用肤螨灵霜治疗，每日３次、１５天为１疗程．Ｃ组５０例，单纯用Ｈｅ－Ｎｅ激光照射，每日１次，每次１５分钟，１５天为１疗程．各组均经１疗程治疗后，Ａ组总有效率８５．９６％；Ｂ组总有效率６２％；Ｃ组总有效率３８％．Ａ组治愈率及总有效率明显高于Ｂ、Ｃ两组，差异显著（Ｐ＜０．０１）．鼻部倒模加Ｈｅ－Ｎｅ激光照射，能明显缩短疗程、提高治愈率．作者认为，将两种治疗方法结合起来，用于治疗非蠕形螨感染引起的酒渣鼻方法简便，无任何痛苦及副作用．     

中药瘢痕膏辅助腹部带蒂皮瓣治疗手部深度烧伤疗效分析

目的：分析中药瘢痕膏辅助腹部带蒂皮瓣治疗手部深度烧伤的临床疗效。方法：选择80例手部深度烧伤患者为研究对象,对照组(40例)采用腹部皮瓣带蒂术治疗,观察组(40例)采用中药瘢痕膏辅助腹部皮瓣带蒂术治疗,观察两组临床疗效,对比两组治疗前后的手指总主动活动度(Total active movement,TAM)、上肢功能指数(The upper extremity functional index,UEFI)及生活质量改善情况,采用视觉模拟评分法(Visual analogue scale,VAS)评价两组疼痛程度,记录两组住院时间、创面愈合时间及不良反应情况。结果：治疗后,观察组总有效率、TAM情况、UEFI、生活质量各项评分均显著高于对照组,差异有统计学意义(P<0.05)。观察组VAS评分、住院时间及创面愈合时间均显著低于对照组,差异有统计学意义(P<0.05)。观察组不良反应发生率与对照组相比,差异无统计学意义(P>0.05)。结论：中药瘢痕膏辅助腹部带蒂皮瓣治疗手部深度烧伤疗效显著,可有效减少患者痛苦,提升生活质量。     

果酸治疗痤疮的效果观察

目的 观察评价果酸[甘醇酸(glycolic acid,GA)]治疗痤疮及痤疮瘢痕的临床疗效,探讨果酸治疗的适应证、方法及安全性.方法 34例痤疮患者,应用浓度为20％、35％、50％、70％的羟基乙酸,进行化学性剥脱治疗,每3周1次,共治疗5次,通过比较治疗前后皮损计数进行疗效观察,观察项目包括:治疗前后毛孔大小、油脂分泌情况、皮肤光滑度、白皙度、瘢痕大小及深浅度,GA治疗对工作生活的影响及疗效满意程度等,并做出疗效评价.结果 34例患者均按计划完成治疗.痊愈4例,显效15例,有效12例,无效3例,总有效率91.18％.治疗后73.53％(25/34)患者毛孔 改善,55.88％(19/34)患者油脂分泌减少,82.35％(28/34)患者皮肤光滑度提高,61.77％(21/34)患者肤色均匀白皙,67.65％(23/34)瘢痕改善.结论 GA适合用于治疗轻、中度痤疮,并能改善毛孔粗大,减少油脂分泌,提高皮肤光滑度,使肤色均匀白皙,减轻痤疮瘢痕,安全且无严重不良反应,患者易于接受,并得较好的评价.     

三种光疗法治疗寻常性痤疮疗效观察

目的：评价光动力学疗法（PDT）,强脉冲光（IPL）和红蓝光（LED）治疗中、重度寻常性痤疮的疗效。方法：将90例中、重度痤疮患者随机分为三组：PDT治疗组,IPL治疗组和LED红蓝光治疗组。分别于治疗前、治疗中期（治疗1个月）和末次治疗结束后评价疗效。结果：治疗中期评价时,PDT、IPL、LED治疗组总有效率分别为93.3%、60.0%和36.7%,平均皮损减少率分别为90.4%、69.0%和39.8%。要达到炎症性皮损痊愈,PDT组平均需要（3±1.52）个治疗周期,IPL组（6±2.15）个治疗周期,LED组（9±3.34）个治疗周期。结论：光疗法治疗中、重度痤疮疗效显著,PDT组疗法效果优于IPL和LED组,副作用少,有很好应用前景,而长期疗效有待进一步观察。     

The Use of Sodium Sulfacetamide 10%-Sulfur 5% Emollient Foam in the Treatment of Acne Vulgaris

Acne vulgaris is the most common disorder encountered in ambulatory clinical practice comprising 11.3 percent of office visits to dermatologists in 2005.¹ By comparison, eczematous dermatoses, psoriasis, and skin cancer accounted for 6.2, 3.5, and 10 percent of office visits, respectively.¹ A variety of topical therapeutic options are available for treatment of acne vulgaris, including benzoyl peroxide, antibiotics, retinoids, azelaic acid, and sodium sulfacetamide-sulfur.^2,3 Sodium sulfacetamide 10%-sulfur 5% has been used for the topical treatment of seborrheic dermatitis, acne vulgaris, and rosacea since the mid-1950s and is available in a variety of formulations, including lotions, creams, cleansers, and emollient foams.⁴ Recently, an emollient foam sodium sulfacetamide 10%-sulfur 5% formulation indicated for topical therapy of acne vulgaris, rosacea, and seborrheic dermatitis has become available.⁵ This article provides an overview of the sodium sulfacetamide 10%-sulfur 5% emollient foam and reports the results of a case report series of patients with acne vulgaris treated with sodium sulfacetamide 10%-sulfur 5% emollient foam as monotherapy or in combination with other topical acne products.The sodium sulfacetamide 10%-sulfur 5% (SSS) emollient foam is formulated as an alcohol-free and fragrance-free topical aerosol foam that has been shown to exhibit moisturization properties.^5,6 An evaluation of the rate of release of the active ingredients from the SSS emollient foam formulation demonstrated active release characteristics conducive to both wash-off and leave-on treatment regimens in clinical practice.⁷ In addition, SSS emollient foam has been shown to markedly reduce colony counts of Propionibacterium acnes in vitro.⁸ Lastly, SSS emollient foam has been shown to exhibit reduced sulfur odor intensity as compared to other conventional SSS formulations,⁹ without the use of potentially sensitizing, odor-masking additives, such as fragrance.     

三种硫磺洗剂治疗Ⅱ度寻常性痤疮疗效观察

目的：观察10%磺胺醋酰钠硫磺洗剂、1%氯霉素硫磺洗剂、5%硫磺洗剂外用治疗Ⅱ度寻常性痤疮的疗效。方法：采取随机对照双盲的方法分组,A组：10%磺胺醋酰钠硫磺洗剂治疗,93例;B组：1%氯霉素硫磺洗剂治疗,89例;C治疗：5%硫磺洗剂治疗,84例。疗程均为8周。结果：A组显效率67.7%,总有效率92.5%;B组显效率47.2%,总有效率79.8%;C组显效率16.7%,总有效率60.7%。A和B组显效率比较具有显著性差异（P〈0.05）,B和C组显效率比较具有显著性差异（P〈0.05）;A和B组的总有效率比较具有显著性差异（P〈0.05）,B和C组的总有效率比较具有显著性差异（P〈0.05）。结论：10%磺胺醋酰钠硫磺洗剂治疗Ⅱ度寻常性痤疮疗效优于1%氯霉素硫磺洗剂,1%氯霉素硫磺洗剂则优于5%硫磺洗剂。     

Nd:YAG(1064nm)激光治疗酒糟鼻毛细血管扩张的临床疗效分析

目的:观察长脉宽Nd:YAG(1 064nm)激光治疗以毛细血管扩张、红斑为主要表现的酒糟鼻的临床疗效。方法:采用长脉宽Nd:YAG(1 064nm)激光对150例酒糟鼻患者的728处毛细血管扩张进行治疗,每2周治疗1次。观察临床疗效,并比较不同病程,不同治疗次数以及不同皮肤Fitzpatrick分型对治疗效果的影响。结果:临床治疗总有效率95.6%(696/728),总显效率65.6%(478/728),不同治疗次数的比较有统计学意义(P0.01),治疗4次以上疗效更好。结论:Nd:YAG(1 064nm)激光能有效治疗酒糟鼻毛细血管扩张,安全性好。     

Microfoam Ultrasound-Guided Sclerotherapy of Varicose Veins in 100 Legs

OBJECTIVE: To demonstrate the efficacy of duplex-guided foam sclerotherapy measured against patient symptom relief and quality of life. METHODS: An analysis was performed of 100 randomly chosen legs with varicose veins treated with ultrasound-guided foam sclerotherapy with a mean follow-up of 22.5 months. RESULTS: An average number of 2.1 treatments using an average of 8.7 mL of foam sclerosing solution were required to close incompetent varicose veins. Thirty-one percent of leg varicose veins required a second treatment at 3 months; 100% of patients felt that their legs were successfully treated with resolution of all symptoms in 85% and resolution in all varicose veins in 92%. CONCLUSION: Ultrasound-guided foam sclerotherapy is effective in treating varicose veins with high patient satisfaction with results and improvement in quality of life.     

Microfoam Ultrasound-Guided Sclerotherapy Treatment for Varicose Veins in a Subgroup with Diameters at the Junction of 10 mm or Greater Compared with a Subgroup of Less Than 10 mm

OBJECTIVE: The objective was to analyze the effectiveness of foam ultrasound-guided sclerotherapy treatment in saphenous veins and tributary veins with a diameter at the saphenofemoral or saphenopopliteal junction of > or =10 mm and compare these results with a subgroup of veins with diameters of < 10 mm. METHODS: A subgroup of 17 saphenous veins with a diameter at the saphenofemoral or saphenopopliteal junction of > or =10 mm were compared with a subgroup of 98 saphenous veins with a diameter of < 10 mm at the saphenofemoral or saphenopopliteal junction for clinical efficacy and patient satisfaction at a mean 2-year follow-up. RESULTS: A mean number of 2.15 treatments utilizing an average of 8.37 mL of foam sclerosing solution (3% sodium tetradecyl sulfate) were required to close all incompetent varicose veins in the < 10-mm group versus a mean of 2.8 treatments and 13.9 mL foam (3% sodium tetradecyl sulfate) for the > or =10-mm group. A total of 27.5% of saphenous veins of < 10 mm and 37.5% of saphenous veins > or = 10 mm required a second treatment at 3 months. One-hundred percent of patients believed that their legs were successfully treated at 2-year follow-up in both groups with 94% of the < 10-mm group noting improvements in quality of life and 100% in the > or =10-mm group. CONCLUSIONS: Ultrasound-guided foam sclerotherapy is effective in treating all sizes of varicose veins with high patient satisfaction and improvement in quality of life. Duplex ultrasound findings demonstrated a small increase in failure to close the saphenofemoral or saphenopopliteal junction with increasing size of junction diameter, but this does not significantly alter the results with respect to clearance of visible varicosities and patient satisfaction with results.     

38例血液透析治疗10年以上慢性肾衰竭患者的生存质量分析

目的：探讨长期血液透析治疗患者的生存质量.方法：对38例血液透析治疗10年以上的慢性肾衰竭患者进行横断面临床研究,项目包括营养状况评估,贫血、钙磷代谢紊乱、继发性甲状旁腺功能亢进、微炎症状态等相关指标的检查,以及患者生活状况的调查.结果：在38例患者中,血压控制在正常范围的患者17例,占44.7%;1级高血压的患者18例,占47.4%.营养正常的患者15例,占39.5%;轻中度营养不良的患者21例,占55.3%;重度营养不良的患者仅2例.血红蛋白是（108.8±15.4）g/L,血清总蛋白是（69.0±11.6）g/L,白蛋白是（38.5±7.0）g/L,铁蛋白是（322.4±242.6）ng/ml,转铁蛋白饱和度是（31.3±11.5）%,高敏C反应蛋白水平是（3.6±3.1）mg/L.其中正常的患者23例,占60.5%;钙磷乘积＜55 mg2/dl2的患者30例,占78.9%;全段甲状旁腺激素＜500 pg/ml的患者21例,占55.3%.生活能自理的患者35例,占92.1%;坚持体育锻炼的患者13例,占34.2%;与亲属关系和睦的患者36例,占94.7%;对目前生活质量满意和较满意的患者32例,占84.2%.结论：慢性肾衰竭的患者通过血液透析治疗,完全能够长期、高质量地存活.     

Open-label Extension Study Evaluating Long-term Safety and Efficacy of FMX103 1.5% Minocycline Topical Foam for the Treatment of Moderate-to-Severe Papulopustular Rosacea

BACKGROUND: Efficacy and safety of FMX103 1.5% for papulopustular rosacea were previously demonstrated in two 12-week, Phase 3 studies. OBJECTIVE: We sought to evaluate the safety and efficacy of FMX103 1.5% foam for up to 52 weeks of treatment. METHODS: Following the completion of two 12-week, double-blind, vehicle-controlled, Phase 3 studies, subjects were invited to enter a 40-week open-label extension study in which all subjects applied FMX103 1.5% once daily. Efficacy endpoints were the reduction in inflammatory lesions and the rate of IGA treatment success from the double-blind baseline. Safety assessments included adverse events, vital signs, laboratory tests, and facial tolerability signs and symptoms. RESULTS: The favorable safety profile of FMX103 1.5% observed in the double-blind studies was maintained over extended treatment lasting up to one year. There were no serious treatment-related adverse events. Long-term treatment with FMX103 1.5% was associated with a greater than 82-percent reduction in inflammatory lesions from baseline and with over 79 percent of subjects achieving treatment success. At the end of the open-label treatment period, over 82 percent of subjects indicated they were overall “satisfied” or “very satisfied” with FMX103 1.5%. All facial local tolerability symptoms improved through Week 52. LIMITATIONS: Due to the nature of the open-label study, lacking a vehicle-treated control, no statistical comparisons can be made. CONCLUSION: FMX103 1.5% demonstrated a favorable safety and tolerability profile for up to 52 weeks. Long-term efficacy was demonstrated by progressive reductions in inflammatory lesions and increasing IGA treatment success, suggesting that FMX103 1.5% may be a suitable option for the treatment for papulopustular rosacea.     

苦参注射液治疗晚期妇科恶性肿瘤临床分析

目的探讨苦参注射液治疗晚期妇科恶性肿瘤的疗效。方法选择52例恶性肿瘤患者（均无手术、放疗、化疗指征）随机分为治疗组（26例,给予一般治疗＋复方苦参注射液10mL/d静滴治疗）和对照组（26例,给予一般治疗）。结果治疗组临床受益率为61.54%,疼痛缓解率为80.00%,腹胀、食欲不振、乏力、睡眠障碍、体重、生活质量改善率分别为69.57%、88.46%、84.62%、72.73%、42.31%、80.77%,0.5年生存率为46.15%,其临床疗效明显优于对照组（P〈0.05）。     

导管引导下泡沫硬化剂治疗精索静脉曲张的疗效分析

目的：探讨泡沫硬化剂栓塞治疗精索静脉曲张（varecocle,VC）的疗效。方法：选择VC患者58例,采用经导管泡沫硬化剂栓塞治疗,对比分析栓塞前后精索静脉主干内径、精液质量的变化,分析其疗效。结果：术后5～30d阴囊坠胀不适等症状消失18例（31．0％）,术后3个月曲张的静脉内径小于1．8mm者48例（82．8％）,大于1．8mm者10例（17．2％）,术后6个月与术前相比,患者精子密度、a＋b级精子活力、精子活动率显著升高,精子畸形率明显降低,两组间差异有统计学意义（P〈0．05）。结论：导管引导下泡沫硬化剂治疗VC疗效确切,能够显著改善VC患者疼痛等不适,提高VC患者精液质量,是一种值得推荐的方法。